- Case report
- Open Access
Secondary extramedullary plasmacytoma of sigmoid colon in a patient with multiple myeloma: a case report
Journal of Medical Case Reports volume 12, Article number: 379 (2018)
Extramedullary plasmacytoma is an uncommon tumor that most often involves the nasopharynx or upper respiratory tract. Extramedullary plasmacytoma is a type of plasma cell neoplasm that can present as a primary tumor or secondary to another plasma cell neoplasm, such as multiple myeloma. Secondary extramedullary plasmacytoma is usually noted in the advanced stages of the disease. Involvement of the gastrointestinal tract occurs in approximately 10% of cases.
A 71-year-old Caucasian woman with known diverticular disease of the colon and multiple myeloma diagnosed 3 years previously, with monoclonal bands of immunoglobulin A, lambda light chains, and multiple osteolytic lesions, presented to our hospital with abdominal pain, abdominal discomfort, and pneumoperitoneum. She underwent left colectomy for diverticulitis with perforation, and an extramedullary secondary colonic plasmacytoma was found in histopathological examination of the sigmoid colon.
Plasmacytoma is known to occur in extraosseous sites. The stomach and small intestine are the most commonly involved sites in the gastrointestinal tract. Secondary extramedullary plasmacytoma of the colon is rare. Colonic plasmacytoma may have varying clinical presentations, such as inflammatory bowel disease and multiple colonic strictures. Although these cases are rare, treating physicians as well as radiologists, pathologists, and surgeons should be aware of this entity.
Plasma cell tumor is an immunoproliferative monoclonal disease of the B-cell line that originates from malignant transformed plasma cells. It is composed almost exclusively of plasma cells that are arranged in clusters or sheets with a scant, delicate, supportive connective tissue stroma. Plasmacytoma and multiple myeloma (MM) are two main groups of plasma cell tumors.
Plasmacytoma includes solitary plasmacytoma of bone and solitary extramedullary plasmacytoma (EMP). Secondary EMP has been reported rarely, and its natural history and diagnosis is not well defined. EMP of the colon is rare [1,2,3].
The presentation of gastrointestinal plasmacytoma is different from that occurring at other sites in the body. The most common presenting symptom is abdominal pain. Symptoms can include rectal bleeding, a change in bowel habits, weight loss, nausea, vomiting, large bowel obstruction, and intussusception . They are generally visible as well-defined soft tissue masses on a computed tomographic (CT) scan and have heterogeneous enhancement on a magnetic resonance imaging (MRI) scan. Larger plasmacytomas can show aggressive traits such as invasion of adjacent fat, bone erosion, or vascular encasement. Positron emission tomography (PET) with 18F-labeled fluoro-2-deoxyglucose/computed tomography has also been found to be useful in staging and follow-up of EMP . We report a case of secondary EMP of the sigmoid colon in a woman with known MM.
A 71-year-old Caucasian woman with known diverticular disease of the colon and MM diagnosed 3 years previously, who was receiving chemotherapy with melphalan, bortezomib (a proteasome inhibitor), and a moderate dose of dexamethasone, presented to the emergency department of our hospital with abdominal pain, abdominal discomfort, and pneumoperitoneum. The clinical examination revealed acute abdomen with free air on an abdominal plain x-ray, and elevated levels of leukocyte cells at 18,000/μl and C-reactive protein at 145 mg/L. The patient had a family history free of cancer, and the last time she underwent colonoscopy was 1 year before admission. She had been diagnosed 3 years previously with stage II MM based on the International Staging System with a β2-microglobulin level of 4.2 mg/L and serum albumin level of 37 g/L. No study was performed for amyloidosis.
An abdominal CT scan showed a 5-cm-wide, 12-cm-long sigmoid mass with medial extension into the fatty tissue at the same localization, pneumoperitoneum, diverticula, free abdominal fluid collections, and distended loops of the small and large intestines (Figs. 1 and 2). The patient was urgently admitted to the operating room as soon as the diagnosis of colonic perforation was established. An exploratory laparotomy was performed, with supra- and subumbilical midline incisions. Intraoperative findings were purulent peritonitis and an obstructive mass of the sigmoid colon causing massive central colonic distention (Figs. 3 and 4). The mass was extending toward the mesosigmoid. It was impossible to define if the mass might be originating from the mesocolon (Fig. 5). After washing the whole abdomen meticulously, exploration revealed colonic perforation in the midtransverse colon at the mesocolic site. The mesocolon at this part was extremely inflammatory and had signs of venous congestion. An extended left colectomy was decided as the operation of choice for this patient. The operation was undertaken in an ontological fashion, with high ligation of the superior mesenteric artery and retrieval of all regional and apical lymph nodes. Peripheral transection was performed at the level of the upper rectum, and after removal of the specimen, a transverse stoma was established (a modified Hartmann’s procedure). Direct anastomosis was considered extremely risky owing to local inflammatory conditions (after peritonitis) and a highly distended colon (after obstruction).
The histopathologic study of the lesion showed large oval cells consisting of a round nucleus in eccentric position with coarse chromatin, protruding nucleolus, and enough cytoplasm (Fig. 6). There were also a few cells with double nuclei as well as giant nuclei. Few cells had the morphology of typical plasmacytes. There were many mitoses. Higher cell apoptosis was observed in the largest part of the tumor. The neoplasm densely infiltrated the muscular wall of the intestine and the pericolic fat without reaching the surface of the serum and without infiltrating the mucosa, which had severe ischemic lesions (Fig. 7). The surgical margins were free. In IHC analysis, the tumor cells were CD20−, CD5−, CD79a+, CD138+ (moderate), CD38+ (moderate), CD56+, CD10−, CD30−, CD117+ (a few), keratins AE1/AE3−, and S-100− (Fig. 8). IHC analysis for both kappa-light and lambda-light chains gave an unreliable effect owing to a very high substrate material (Fig. 9). The Ki-67 cell proliferation index was approximately 40%. In the lymph nodes, morphologically and with CD138 and CD38 immunostaining in selected sections, infiltration by the neoplastic cell population was not documented. The patient did well postoperatively.
Hematological malignancies form a diverse group depending on their origin from bone marrow cells. They can be broadly classified as neoplasms of myeloid cell lines, neoplasms of lymphoid cell lines, lymphoproliferative disorders, and histiocytic/dendritic cell neoplasms.
Plasma cell neoplasm (PCN) is a type of hematological malignancy arising as a result of monoclonal proliferation of plasma cells (lymphoid cell line) and is associated with production of monoclonal proteins. These malignancies include monoclonal gammopathy of undetermined significance, solitary plasmacytoma of the bone, EMP, and MM.
EMP is a type of PCN that can present as a primary tumor or secondary to another PCN, such as MM. In the primary subtype, it occurs alone in the absence of another PCN, unlike in the secondary subtype, often with MM. MM is a monoclonal, immunoproliferative plasma cell neoplasm of the B-lymphoid cells. Secondary EMP is usually noted in the advanced stages of the disease. Primary and secondary EMPs mainly affect the upper aerodigestive tract (nasopharynx, oropharynx, hypopharynx, larynx, trachea, and esophagus).
EMP represents approximately 3% of all PCNs and occurs when malignant plasmablastic clones migrate into soft tissues. Plasmacytomas, first described by Schridde in 1905, are clonal proliferations of plasma cells that are cytologically and immunophenotypically identical to plasma cell myeloma but manifest a localized osseous or extraosseous growth pattern . They are rare diseases, and the understanding of their epidemiologic features and clinical outcomes is derived largely from compilations of cases reported in the literature and in small clinical series .
The pathophysiological mechanism of EMPs is not yet fully determined. One suggestion is that MM cells and the bone marrow microenvironment tightly interact with each other. This is mediated by multiple soluble factors and adhesion molecules. Integrins acting as receptors on stromal cells and the extracellular matrix play an important role in the homing of MM cells in the bone marrow . Changes in these adhesion molecules and integrins can lead to the migration of MM cells to the bloodstream (plasma cell escape) and finally to the development of an extraosseous plasmacytoma. In addition, in order for plasma cells to migrate outside the bone marrow, genetic changes must occur that give these migrating plasma cells their aggressive nature. Recent studies have investigated the expression of several glycoproteins in MM. Mutations in genes encoding these proteins, such as P53, play a major role in the aggressive character of the disease. P53 is a nuclear protein that provides genomic stability by regulating the cell cycle. Another protein, CD56, is usually present as a membrane glycoprotein on natural killer cells and T cells and is involved in cell adhesion and migration. CD56 is expressed in more than 70% of plasma cells in MM; however, it is not expressed in normal plasma cells. There is evidence that CD56 is downregulated in extramedullary MM.
Three-fourths of EMP cases are in males. EMP progresses to MM within 10 years in 11–30% of patients. Overall survival in 10 years is 70%. The median age of patients with either solitary bone plasmacytoma or EMP is 55 years. This median age is 10 years younger than that of patients with MM. EMP presents as a mass growing in the aerodigestive tract in 80–90% of patients, often with spread to lymph nodes, although other sites are affected as well.
Common complaints include swelling, headache, nasal discharge, epistaxis, nasal obstruction, sore throat, hoarseness, dysphonia, dysphagia, dyspnea, epigastric pain, and hemoptysis [9,10,11,12]. Symptoms arising from EMP in other tissues are associated with the site of the tumor, tumor size, and compression and/or involvement of the surrounding structures.
EMP involving the lung most commonly presents as a pulmonary nodule or hilar mass. Although EMP can occur in any site, 80–90% of tumors develop in the head and neck area, especially in the aerodigestive tract. Approximately 80% of cases involve the paranasal sinuses, pharynx, nasal cavity, or gums and oral mucosa [9, 12,13,14,15]. A mass (plasmacytoma) in these areas is the most common finding, with compression or invasion of the surrounding structures. Patients with tumors involving the base of the skull may present with cranial nerve palsies. Case reports of involvement of the urinary bladder, central nervous system, orbit, gastrointestinal tract (GIT), liver, spleen, pancreas, lung, breast, skin, testis, parotid gland, mediastinum, and thyroid gland (associated with goiter and Hashimoto thyroiditis) exist in the literature [9, 12,13,14,15,16].
In 30–40% of cases, local lymph nodes are involved at presentation or upon relapse. Because of the presentation of EMP in the mucosa of the aerodigestive tract (> 80%), the etiology may be related to chronic stimulation of inhaled irritants or viral infection. CT scanning, MRI, and complete endoscopic examination of the aerodigestive and gastrointestinal tracts are required to determine the exact extent of the tumor and its potential for resectability . These lesions may be associated with variable mass effect; infiltration and/or destruction of adjacent bone, muscle, and fat; and vascular encasement .
EMP biopsy of the soft tissue lesion shows infiltration by monoclonal plasma cells. In EMP, the soft tissue lesion commonly exhibits submucosal growth, requiring deep biopsy, open biopsy, or complete excision, depending on the tumor location .
Prognosis and long-term follow-up of primary isolated EMP in the colon are not well known. Gupta et al. reported no recurrent tumor at 17-month follow-up in a case of EMP invading all the layers of the colon with metastases in three lymph nodes after postoperative adjuvant chemotherapy . However, Doki et al. reported a recurrent case 4 months after operation . Chemotherapy was not effective in that case; the patient died just 6 months after the tumor relapse.
The prognosis of primary EMP is generally good. Liebross et al. reported that median survival of 9.5 years, and 56% of patients were free from systemic disease at 5 years . One-third of patients with EMP had MM after a median follow-up of 1.8 years.
Development of visceral secondary EMP involving the GIT in the course of MM (a monoclonal, immunoproliferative PCN of the B-lymphoid cells) is extremely rare, estimated to occur in 0.9% of cases . Only 17 cases of EMP affecting the ileum have been reported in the English-language literature, almost all primary in nature , with only three previous cases of EMP secondary to MM reported [21,22,23].
Our patient was receiving chemotherapy for MM. In general, EMPs are considered to be radiosensitive, with a local control rate of 90–100% . Allison et al. proposed surgery, radiotherapy (RT), and chemotherapy for gastrointestinal plasmacytomas according to the degree of disease extent .
Colonic plasmacytoma occurs only rarely, and a definitive algorithm for treatment has not been determined. Endoscopic treatments such as submucosal resection or polypectomy have proven to be sufficient in selected cases [25,26,27]. RT is the preferred treatment for anal canal and rectal lesions [28, 29]. An extensive review of over 400 publications done by Alexiou et al. provided evidence that surgery alone gives the best results in cases of solitary plasmacytoma when resectability is good. However, if complete surgical tumor resection is doubtful or impossible and/or if lymph node areas are affected, then combined therapy (surgery and radiation) is recommended . In one recent series with 80 patients, younger patients, especially those with head and neck lesions and without pre-RT macroscopic tumors, seemed to have the best outcome when treated with RT, either with or without surgery .
In only one randomized trial of chemotherapy did patients receiving melphalan and prednisone show an improved disease-free survival rate . The use of adjuvant chemotherapy is recommended for patients with higher-grade disease, local treatment failure (tumor size > 5 cm), or refractory disease .
Patients with EMP characteristically present with localized disease, and the incidence of lymph node involvement is 10–20%. The overall 10+-year survival rate is 70% . Survival rates range from more than 90% among patients with EMP arising in the skin or lymph nodes to 48% for those with eye, brain, and central nervous system tumors . Progression to MM varies from 10% to 30% in EMP. In a series with 258 patients (52 with EMP), bone localization was found to be the only predictor of MM development in multivariate analyses . When progression to MM occurs, it usually does so within the first 2 years. Follow-up radiological and electrophoresis assessments are required after treatment to detect recurrence and progression to MM .
EMPs are rarely seen in the GIT. It is important to consider this possibility during the evaluation of a mass in the GIT because placmacytomas of GIT have different treatment and follow-up modalities than adenocarcinomas and other tumors of the GIT. Surgical treatment is usually sufficient in localized solitary plasmacytoma of the GIT.
In cases of secondary EMP, radiotherapy or surgery alone is insufficient, and systemic therapy is required. In younger patients, the use of immunomodulatory drugs with induction agents in combination with autologous hematopoietic stem cell transplant results in higher remission rates and overall survival . The prognosis of secondary EMP with gastrointestinal involvement is unknown. However, the small number of cases reported in the literature indicates a poor prognosis [21,22,23, 34,35,36]. The role of surgery in secondary EMP is often palliative, to deal with resolvable life-threatening emergencies, and, where possible, to prolong life.
The prognosis of intestinal EMP is unclear. In nine selected patients with MM-associated EMPs, Vaiopoulos et al.  reported a median survival of 4.6 years, and none of the patients had intestinal involvement. Two cases involving the intestinal tract presented by Griffiths et al. had fatal outcomes not long after diagnosis with EMP .
Because secondary EMP in the colon is rare, the clinical course, treatment guidelines, and prognosis are not very well defined. To provide adequate treatment, further study of the clinical features of secondary EMP of the colon is necessary.
Magnetic resonance imaging
Plasma cell neoplasm
Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52(3):245–9.
Hampton JM, Gandy JR. Plasmacytoma of the gastro-intestinal tract. Ann Surg. 1957;145(3):415–22.
Asselah F, Crow J, Slavin G, Sowter G, Sheldon C, Asselah H. Solitary plasmacytoma of the intestine. Histopathology. 1982;6(5):631–45.
Gupta V, Nahak B, Sakhuja P, Agarwal AK, Kumar N, Mishra PK. Primary isolated extramedullary plasmacytoma of colon. World J Surg Oncol. 2007;5:47.
Makis W, Ciarallo A, Hickeson M, Lisbona R. Gastric recurrence of a primary colon plasmacytoma: staging and evaluating response to therapy with 18F-FDG PET/CT. Br J Radiol. 2012;85(1009):e4–9.
Schridde H. Weitere Untersuchungen uber die Kornelungen der Plasmazellen. Centralbl Allg Pathol Pathol Anat. 1905;16:433–5.
Chang YL, Chen PY, Hung SH. Extramedullary plasmacytoma of the nasopharynx: a case report and review of the literature. Oncol Lett. 2014;7(2)):458–60.
Katz BZ. Adhesion molecules—the lifelines of multiple myeloma cells. Semin Cancer Biol. 2010;20:186–95.
Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000;85(1):47–51.
Krishnasamy G, Dhanasekar G. Extramedullary plasmacytoma of postnasal space. Kulak Burun Bogaz Ihtis Derg. 2013;23(3):183–6.
Belić B, Mitrović S, Arsenijević S, Erdevicki L, Stojanović J, Stojanović S, et al. Nasal septum extramedullary plasmacytoma. Vojnosanit Pregl. 2013;70(2):221–4.
Erdogan BA, Sekercan O, Dursun N, Tatar G, Bora F. Extramedullary plasmacytoma of maxillary sinus. J Craniofac Surg. 2013;24(1):e85–7.
Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am. 1999;13(6):1249–57.
Wiltshaw E. The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore). 1976;55(3):217–38.
Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–14.
Puliga G, Olla L, Bellisano G, Di Naro N, Ganau M, Lai ML, et al. Solitary extramedullary plasmacytoma of the thyroid gland associated with multinodular goiter: case report and review of the literature. Pathologica. 2011;103(3):61–3.
Ooi GC, Chim JC, Au WY, Khong PL. Radiologic manifestations of primary solitary extramedullary and multiple solitary plasmacytomas. AJR Am J Roentgenol. 2006;186(3):821–7.
Susnerwala SS, Shanks JH, Banerjee SS, et al. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997;75(6):921–7.
Doki T, Takeuchi O, Kaiho T, Tsuchiya S, Matsuzaki O, Miyazaki M. Primary isolated extramedullary plasmacytoma of the colon. Int J Colorectal Dis. 2008;23(7):719–20.
Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, et al. Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica. 2006;91:964–7.
Dzierzanowski M, Porter GA. An unusual presentation of a secondary extramedullary plasmacytoma in a patient with multiple myeloma. Can J Surg. 2005;48:75–6.
Hill SA, Yudelman PL. Multiple myelomatosis: an unusual cause of small bowel intussusception. Postgrad Med J. 1986;62:1043–4.
Tauscher AE, Orme DK, Forster J, Damjanov I. Plasmacytoma-associated obstruction of the small intestine in a patient with multiple myeloma. Hosp Physician. 2002;38(9):46–8, 67.
Allison JG, Getaz EP, Staples WG. Primary isolated extramedullary plasmacytoma of the colon: a case report. S Afr Med J. 1977;51(24):893–5.
Nakagawa Y, Nagai T, Okawara H, et al. Minute primary extramedullary plasmacytomas of the large intestine. Endoscopy. 2011;43(2):E105–6.
Gabriel EM, Savu M. Discovery of a rare ileocecal plasmacytoma. J Surg Case Rep. 2014, 2014(3):rju016.
Kodani T, Osada T, Terai T, et al. Successful endoscopic mucosal resection of a solitary extramedullary plasmacytoma in the sigmoid colon. Endoscopy. 2011;43(2):E298–9.
Price A, Quilty PM, Ludgate SM. Extramedullary plasmacytoma of the rectum: two cases treated by radiotherapy. Clin Radiol. 1987;38(3):283–5.
Antunes MI, Bujor L, Grillo IM. Anal canal plasmacytoma—an uncommon presentation site. Rep Pract Oncol Radiother. 2011;16(1):36–39.
Kilciksiz S, Celik OK, Pak Y, et al. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. Am J Hematol. 2008;83(9):702–7.
Avilés A, Huerta-Guzmán J, Delgado S, Fernández A, Díaz-Maqueo JC. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14(3):111–7.
Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004. Br J Haematol. 2009;144(1):86–94.
Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–7.
Lopes Da Silva R. Extramedullary plasmacytoma of the small intestine: clinical features, diagnosis and treatment. J Dig Dis. 2012;13:10–8.
Vaiopoulos G, Viniou N, Plata E, Konstantopoulos K, Andreopoulos A, Rombos Y, et al. Development of plasma cell tumours during treatment of multiple myeloma. Ann Hematol. 1996;72:317–20.
Griffiths AP, Shepherd NA, Beddall A, Williams JG. Gastrointestinal tumour masses due to multiple myeloma: a pathological mimic of malignant lymphoma. Histopathology. 1997;31:318–23.
Availability of data and materials
Data sharing is not applicable to this article, because no datasets were generated or analyzed during the present study.
Ethics approval and consent to participate
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fagkrezos, D., Manes, K., Paraskeva, K. et al. Secondary extramedullary plasmacytoma of sigmoid colon in a patient with multiple myeloma: a case report. J Med Case Reports 12, 379 (2018). https://doi.org/10.1186/s13256-018-1888-4
- Secondary extramedullary plasmacytoma
- Sigmoid colon
- Multiple myeloma